Table 3.
Summary of prevalence estimates for males, females, and both at baseline and for each modeled scenario, showing first and last year of available data.
| Male prevalence per 100,000 |
Female prevalence per 100,000 |
Overall prevalence per 100,000 |
||||
|---|---|---|---|---|---|---|
| 2020 | 2116 | 2020 | 2116 | 2020 | 2116 | |
| Baseline | 9.34 | 11.12 | 7.88 | 8.65 | 8.58 | 9.67 |
| Scenario 1 (overall 3-month survival increase) |
10.16 | 12.15 | 8.57 | 9.44 | 9.34 | 10.56 |
| Scenario 2 (50% survival increase in SOD1 mutation carriers) |
9.52 | 11.34 | 8.04 | 8.82 | 8.75 | 9.87 |
| Scenario 3 (50% survival increase in C9orf72 mutation carriers) |
9.80 | 11.68 | 8.27 | 9.08 | 9.01 | 10.16 |
| 2020 | 2066 | 2020 | 2066 | 2020 | 2066 | |
| Baseline | 9.34 | 10.55 | 7.88 | 8.67 | 8.58 | 9.50 |
| Scenario 4 (halt progression in C9orf72 mutation carriers)a |
14.55 | 17.24 | 12.44 | 14.36 | 13.49 | 15.68 |
a
Scenario 4 comparisons are shown for the years 2020 and 2066, which is the last year for which projected life expectancy data is available.